968 related articles for article (PubMed ID: 31570017)
1. Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation.
Elangovan A; Allegretti JR; Fischer M
Expert Opin Biol Ther; 2019 Dec; 19(12):1343-1355. PubMed ID: 31570017
[No Abstract] [Full Text] [Related]
2. Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: an update.
Holleran G; Scaldaferri F; Ianiro G; Lopetuso L; Mc Namara D; Mele MC; Gasbarrini A; Cammarota G
Drugs Today (Barc); 2018 Feb; 54(2):123-136. PubMed ID: 29637938
[TBL] [Abstract][Full Text] [Related]
3. The role of the gut microbiome in colonization resistance and recurrent
Seekatz AM; Safdar N; Khanna S
Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
[TBL] [Abstract][Full Text] [Related]
4. Expert opinion on fecal microbiota transplantation for the treatment of
Kumar V; Fischer M
Expert Opin Biol Ther; 2020 Jan; 20(1):73-81. PubMed ID: 31690143
[No Abstract] [Full Text] [Related]
5. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation.
Shen ZH; Zhu CX; Quan YS; Yang ZY; Wu S; Luo WW; Tan B; Wang XY
World J Gastroenterol; 2018 Jan; 24(1):5-14. PubMed ID: 29358877
[TBL] [Abstract][Full Text] [Related]
6. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.
Lee CH; Chai J; Hammond K; Jeon SR; Patel Y; Goldeh C; Kim P
Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1731-1735. PubMed ID: 31165961
[TBL] [Abstract][Full Text] [Related]
7. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans.
Staley C; Khoruts A; Sadowsky MJ
Arch Med Res; 2017 Nov; 48(8):766-773. PubMed ID: 29183720
[TBL] [Abstract][Full Text] [Related]
9. Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection.
Crow JR; Davis SL; Chaykosky DM; Smith TT; Smith JM
Pharmacotherapy; 2015 Nov; 35(11):1016-25. PubMed ID: 26598094
[TBL] [Abstract][Full Text] [Related]
10. Role of Probiotics in Human Gut Microbiome-Associated Diseases.
Kim SK; Guevarra RB; Kim YT; Kwon J; Kim H; Cho JH; Kim HB; Lee JH
J Microbiol Biotechnol; 2019 Sep; 29(9):1335-1340. PubMed ID: 31434172
[TBL] [Abstract][Full Text] [Related]
11. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis.
Dang X; Xu M; Liu D; Zhou D; Yang W
PLoS One; 2020; 15(3):e0228846. PubMed ID: 32182248
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
Vemuri RC; Gundamaraju R; Shinde T; Eri R
Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
[TBL] [Abstract][Full Text] [Related]
13. Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders.
Ianiro G; Segal JP; Mullish BH; Quraishi MN; Porcari S; Fabiani G; Gasbarrini A; Cammarota G
Future Microbiol; 2020 Aug; 15():1173-1183. PubMed ID: 32954843
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic and Modulation of Microbiota: A New Paradigm?
Rizzatti G; Ianiro G; Gasbarrini A
J Clin Gastroenterol; 2018; 52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017():S74-S77. PubMed ID: 29912755
[TBL] [Abstract][Full Text] [Related]
15. Fecal microbiota transfer for bowel disorders: efficacy or hype?
Schmulson M; Bashashati M
Curr Opin Pharmacol; 2018 Dec; 43():72-80. PubMed ID: 30218939
[TBL] [Abstract][Full Text] [Related]
16. Fecal microbiota transplantation: a review on current formulations in
Rakotonirina A; Galperine T; Allémann E
Expert Opin Biol Ther; 2022 Jul; 22(7):929-944. PubMed ID: 35763604
[TBL] [Abstract][Full Text] [Related]
17. Fecal microbiota transplantation for Clostridium difficile infection: back to the future.
Borgia G; Maraolo AE; Foggia M; Buonomo AR; Gentile I
Expert Opin Biol Ther; 2015 Jul; 15(7):1001-14. PubMed ID: 26063385
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
Haak BW; Prescott HC; Wiersinga WJ
Front Immunol; 2018; 9():2042. PubMed ID: 30250472
[TBL] [Abstract][Full Text] [Related]
19. Role of the microbiome, probiotics, and 'dysbiosis therapy' in critical illness.
Wischmeyer PE; McDonald D; Knight R
Curr Opin Crit Care; 2016 Aug; 22(4):347-53. PubMed ID: 27327243
[TBL] [Abstract][Full Text] [Related]
20. Pros and cons: Is faecal microbiota transplantation a safe and efficient treatment option for gut dysbiosis?
Marrs T; Walter J
Allergy; 2021 Jul; 76(7):2312-2317. PubMed ID: 33483999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
